Blood Collection
ProcedurePeripheral blood collection via routine venipuncture
NCT Number: NCT04264767
Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue.
This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.
Looking for future studies?
Notify Me22 year–80 year
All sexes
Observational
Sourasky Medical Center, Tel Aviv, Israel
The aim of this study is to characterize methylation patterns that will distinguish cancer from normal samples and will be able to recognize the origin of the cancer by collecting cfDNA (circulating free DNA) from blood samples collected from patients with a new diagnosis of cancer and from healthy volunteers who do not have diagnosis or history of cancer. Identifying those methylation patterns may assist in the development of blood test that will be able to detect the presence and the origin of wide range of human cancers
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Cases:
Exclusion criteria
- Cases:
Inclusion criteria
- Controls:
Exclusion criteria
- Controls:
Peripheral blood collection via routine venipuncture
Time frame: 72 Months
To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer
Time frame: 72 Months
To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples
Nucleix Ltd.
Industry
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA, An Observational Multicenter Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04826458
Cancer, Hematologic Diseases
Meldola, FC, Italy
View Trial DetailsNCT04419623
Blood Cancer, COVID-19
Augusta, Georgia, United States
View Trial DetailsNCT03560882
Acute Myeloid Leukemia, Bone Marrow Diseases
Fairway, Kansas, United States
View Trial DetailsNCT02041416
Cancer, Hematologic Diseases
Duarte, California, United States
View Trial Details